Population pharmacokinetic approach to evaluate the effect of <i><scp>CYP2D6</scp>, <scp>CYP3A</scp>, <scp>ABCB1</scp>, <scp>POR</scp></i> and <i><scp>NR1I2</scp></i> genotypes on donepezil clearance

Abstract

The pharmacokinetic parameters of donepezil were well described by the developed population model. Functional alleles of CYP2D6 significantly contributed to the variability in donepezil disposition in the patient population and should be further investigated in the context of individual dose optimization to improve clinical outcome and tolerability of the treatment.